Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea.
Korean J Intern Med. 2010 Jun;25(2):213-6. doi: 10.3904/kjim.2010.25.2.213. Epub 2010 Jun 1.
We described here a patient who had two lung masses. Although the two masses had the same histology and a similar good response to initial chemotherapy with gemcitabine and carboplatin, the response to pemetrexed as a second-line treatment was different after re-growth of the tumors. These two lung masses could have originated from different clones or they could have progressed through different paths of molecular pathogenesis after metastasis, which would lead to different tumor characteristics, including their chemosensitivity. Regardless of their pathogenetic mechanisms, it seems important to recognize that tumors with the same histology that develop in one patient can have different responses to drugs.
我们在此描述了一位患有两个肺部肿块的患者。尽管这两个肿块具有相同的组织学特征,并且对最初的吉西他滨和顺铂化疗反应良好,但在肿瘤重新生长后,培美曲塞作为二线治疗的反应不同。这两个肺部肿块可能来自不同的克隆,或者在转移后通过不同的分子发病机制途径进展,这将导致不同的肿瘤特征,包括其化疗敏感性。无论其发病机制如何,似乎重要的是要认识到,在同一患者中发展的具有相同组织学特征的肿瘤对药物可能有不同的反应。